Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells.

Abnormalities in the STAT3 pathway are involved in the oncogenesis of several cancers. However, the mechanism by which dysregulated STAT3 signaling contributes to the progression of human colorectal cancer (CRC) has not been elucidated, nor has the role of JAK, the physiological activator of STAT3, been evaluated. To investigate the role of both JAK and STAT3 in CRC progression, we inhibited JAK with AG490 and depleted STAT3 with a SiRNA. Our results demonstrate that STAT3 and both JAK1 and 2 are involved in CRC cell growth, survival, invasion, and migration through regulation of gene expression, such as Bcl-2, p1(6ink4a), p21(waf1/cip1), p27(kip1), E-cadherin, VEGF, and MMPs. Importantly, the FAK is not required for STAT3-mediated regulation, but does function downstream of JAK. In addition, our data show that proteasome-mediated proteolysis promotes dephosphorylation of the JAK2, and consequently, negatively regulates STAT3 signaling in CRC. Moreover, immunohistochemical staining reveals that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive correlation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas. Therefore, our findings illustrate the biologic significance of JAK1, 2/STAT3 signaling in CRC progression and provide novel evidence that the JAK/STAT3 pathway may be a new potential target for therapy of CRC.

[1]  Prahlad T. Ram,et al.  Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. , 2000, Science.

[2]  H. Allgayer,et al.  Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer , 2007, Clinical Cancer Research.

[3]  Jingwen Liu,et al.  Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells , 2003, Oncogene.

[4]  A. Walch,et al.  STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation , 2006, Journal of Clinical Pathology.

[5]  D. Frank,et al.  STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas , 2007, Oncogene.

[6]  R Nyga,et al.  The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation , 2007, Oncogene.

[7]  F. Ciardiello,et al.  Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer , 2007, Oncogene.

[8]  Hans C Clevers,et al.  Molecular causes of colon cancer , 2002, European journal of clinical investigation.

[9]  Kenichi Matsubara,et al.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.

[10]  Shan Wang,et al.  Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. , 2004, World journal of gastroenterology.

[11]  D. Levy,et al.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.

[12]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Brand,et al.  Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease , 2007, Gut.

[14]  W. Klapper,et al.  High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma , 2007, Leukemia.

[15]  Z. Yi,et al.  Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. , 2007, Blood.

[16]  Li Li,et al.  Autocrine-mediated Activation of STAT3 Correlates with Cell Proliferation in Breast Carcinoma Lines* , 2002, The Journal of Biological Chemistry.

[17]  Jing-Yuan Fang,et al.  Inhibition of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Decreases DNA Methylation in Colon Cancer Cells* , 2007, Journal of Biological Chemistry.

[18]  P. Dent,et al.  Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. , 2005, Molecular cancer therapeutics.

[19]  Toshiyuki Nakayama,et al.  Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. , 2006, Oncology reports.

[20]  Lothar Schweigerer,et al.  Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas , 2004, Cancer Research.

[21]  S. Fan,et al.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. , 2000, Annals of surgery.

[22]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[23]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[24]  J. Pober,et al.  Interleukin-11 Up-Regulates Survivin Expression in Endothelial Cells through a Signal Transducer and Activator of Transcription-3 Pathway , 2001, Laboratory Investigation.

[25]  S. Nagata,et al.  Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Milano,et al.  JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. , 2006, European journal of cancer.

[27]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[28]  T. Nagayasu,et al.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors , 2005, Journal of Clinical Pathology.

[29]  Sanjeev Banerjee,et al.  Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. , 2007, Cancer research.

[30]  A. Mottok,et al.  Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. , 2007, Blood.

[31]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[33]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[34]  Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. , 2007, Gut.

[35]  Didier Merlin,et al.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. , 2007, Cancer research.

[36]  Y. Miyagi,et al.  Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. , 2007, Cancer research.

[37]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[38]  M. Fornaro,et al.  Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway* , 2003, Journal of Biological Chemistry.

[39]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Curran,et al.  Profiling markers of prognosis in colorectal cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  T. Toyama,et al.  Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells , 2003, Oncogene.

[42]  D. Neri,et al.  The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. , 2007, Cancer research.

[43]  T. Chiba,et al.  Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway , 2003, Oncogene.

[44]  M. Meyerson,et al.  Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. , 2006, Cancer research.

[45]  Guoqiang Chen,et al.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. McDonnell,et al.  Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma , 2003, Oncogene.